Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.

Autor: Piovesan D; Arcus Biosciences, Hayward, California., Tan JBL; Arcus Biosciences, Hayward, California.; Nkarta Inc., South San Francisco, California., Becker A; Arcus Biosciences, Hayward, California.; Departments of Pediatrics, Cell and Developmental Biology, Weill Cornell Medical College, New York, New York., Banuelos J; Arcus Biosciences, Hayward, California., Narasappa N; Arcus Biosciences, Hayward, California.; Nurix Therapeutics, San Francisco, California., DiRenzo D; Arcus Biosciences, Hayward, California., Zhang K; Arcus Biosciences, Hayward, California.; Allogene Therapeutics, South San Francisco, California., Chen A; Arcus Biosciences, Hayward, California., Ginn E; Arcus Biosciences, Hayward, California., Udyavar AR; Arcus Biosciences, Hayward, California.; Instil Bio Inc., Thousand Oaks, California., Yin F; Arcus Biosciences, Hayward, California.; BeiGene USA, Inc., San Mateo, California., Paprcka SL; Arcus Biosciences, Hayward, California., Purandare B; PACT Pharma Inc., South San Francisco, California., Park TW; Arcus Biosciences, Hayward, California., Kimura N; Arcus Biosciences, Hayward, California., Kalisiak J; Arcus Biosciences, Hayward, California., Young SW; Arcus Biosciences, Hayward, California., Powers JP; Arcus Biosciences, Hayward, California., Schindler U; Arcus Biosciences, Hayward, California., Sivick KE; Arcus Biosciences, Hayward, California., Walters MJ; Arcus Biosciences, Hayward, California.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 948-959.